Medicine composition used for treating hypertension

A composition and high blood pressure technology, applied in the direction of drug combination, pharmaceutical formula, cardiovascular system diseases, etc., can solve the problem of rosuvastatin calcium, and the drug composition of aliskiren and rosuvastatin calcium, which is not disclosed Pharmacodynamic tests and their results and other issues, to achieve good preventive effect, kidney protection, and good synergistic effects

Active Publication Date: 2012-05-30
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application did not mention rosuvastatin calcium throughout, and did not disclose the ph

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition used for treating hypertension
  • Medicine composition used for treating hypertension
  • Medicine composition used for treating hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 Pharmaceutical composition common tablet of the present invention

[0022] Rosuvastatin Calcium 1g

[0023] Aliskiren 120g

[0024] Starch 140g

[0025] Dextrin 120g

[0026] 50% ethanol appropriate amount

[0027] Magnesium Stearate 1.0g

[0028] Preparation process: Weigh the prescribed amount of rosuvastatin calcium, aliskiren, starch, and dextrin and mix evenly. In addition, add an appropriate amount of 50% ethanol to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 2

[0029] Embodiment 2 Pharmaceutical composition capsule of the present invention

[0030] Rosuvastatin Calcium 1g

[0031] Aliskiren 3.75g

[0032] Microcrystalline Cellulose 300g

[0033] Micronized silica gel 12g

[0034] Preparation process: Grind rosuvastatin calcium, aliskiren, microcrystalline cellulose, and micropowder silica gel through a 100-mesh sieve, mix well, and directly fill capsules.

Embodiment 3

[0035] Embodiment 3 Pharmaceutical composition bilayer tablet of the present invention

[0036] Rosuvastatin Calcium 10g

[0037] Mannitol 10g

[0038] Lactose 40g

[0039] Microcrystalline Cellulose 20g

[0040] 6% PVP in 95% ethanol solution 120g

[0041] Magnesium stearate 2g

[0042] Preparation process a: Rosuvastatin calcium is passed through a 100-mesh sieve, mannitol, lactose, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescription amount of rosuvastatin calcium is weighed and mixed with mannitol, lactose, and microcrystalline cellulose evenly , adding 6% PVP in 95% ethanol solution in an appropriate amount to granulate, drying at 60°C, sieving the dry granules with a 16-mesh sieve, and adding a prescribed amount of magnesium stearate to the dry granules.

[0043] Aliskiren 37.5g

[0044] Pregelatinized starch 50g

[0045] Mannitol 50g

[0046] 6% PVP in 95% ethanol solution 100g

[0047] Micronized silica gel 5g

[0048] Prepa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine composition used for treating hypertension and an application thereof. The invention provides a medicine composition, containing aliskiren and rosuvastatin, aiming at improving a curative effect, improving prognosis of a patient, reducing occurrence of cardiovascular and cerebrovascular diseases caused by the hypertension and improving effective protection on important organs of a hyperpietic such as heart, brain, kidney and the like. Pharmacodynamic experiments verify that the medicine composition provided by the invention has synergic treatment effects in the aspects of reducing blood pressure, reversing or alleviating left ventricular hypertrophy and reducing microdose albumin in urine, is effective in the aspect of preventing hypertensive renal disease and can delay or reduce occurrence of nephropathy of the hyperpietic.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating hypertension, in particular to a pharmaceutical composition containing aliskiren and rosuvastatin calcium. Background technique [0002] With the continuous improvement of people's living standards and the deterioration of the environment, the number of patients with cardiovascular diseases such as hypertension, hyperlipidemia and hypercholesterolemia is increasing day by day. Hypertension is a chronic disease with a high incidence rate and an important risk factor for cardiovascular diseases. It can cause damage to the brain, heart, kidney and blood vessels of hypertensive patients. Clinically, stroke, coronary heart disease, Cardiac arrhythmia, heart failure, renal insufficiency, arterial embolism and other related diseases have high mortality and disability rates, which seriously affect the physical and mental health of hypertensive patients. [0003] The antihypertensive drug Alisk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/505A61K31/165A61P9/12A61P9/00A61P9/04
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap